Collaboration Antigens definition

Collaboration Antigens means any antigen encoded by hepatitis B virus, including any such antigen selected by the JRC for inclusion in a Tarmogen to be Developed under the Agreement, and any modified versions or derivatives thereof.
Sample 1Sample 2Sample 3
Collaboration Antigens means any or all of the A1 Antigen, the A2 Antigen, the A3 Antigen, or any Replacement Antigen that is included as a Collaboration Antigen in a Collaboration Antigen Exchange in accordance with Section 2.3, as the context requires.
Sample 1Sample 2

Examples of Collaboration Antigens in a sentence

  • Unless otherwise agreed by AZ, such additional activities with respect to a Collaboration Antigen shall be performed by ABX (provided that, unless ABX otherwise consents in writing, all such additional work for all Collaboration Antigens does not exceed [Confidential treatment requested] additional FTEs in the aggregate for each year).

  • The exclusivity restrictions with respect to AZ (but, subject to the last sentence of this Section 16.8.2(a)(iv), not ABX (or its successor)) in Article 17 shall terminate with respect to such Collaboration Antigen(s) and AZ shall have the right to grant sublicenses under the license granted in Section 4.1 with respect to such Collaboration Antigen, through multiple tiers of sublicensees, to its Affiliates and to any other Persons.

  • AZ or its Affiliates shall perform all of its responsibilities under this Section 2.3.5, provided that AZ shall have the right to use subcontractors, reasonably acceptable to ABX, to perform any such responsibilities subject to Section 4.2.3. Nothing in this Section 2.3.5 shall restrict AZ’s right, in its sole discretion and at its sole cost and expense, to Exploit Non-Licensed Products with respect to Collaboration Antigens itself or with or through one or more Affiliates or Third Parties.

  • The initial Proposed Antigens designated by AZ, as of the Effective Date, for selection by the Research Management Committee as Collaboration Antigens are set forth in Exhibit A-2.

  • AZ’s obligation to pay milestones and royalties to ABX shall continue with respect to such Collaboration Antigen(s) but the milestone payments set forth in Section 9.3.1 and the royalty rate payable to ABX under Section 9.3.2 on Net Sales of Licensed Products that bind to and are directed against such Collaboration Antigen(s) shall be reduced to the applicable amounts and rates set forth in Exhibit O in addition to any other reductions required under Article 9.

  • The license and other rights granted by ABX to AZ under Section 4.1 with respect to such Collaboration Antigen(s) shall continue without the obligations and restrictions on AZ under Articles 2, 3, the last two sentences of Section 4.1, Section 4.12.1, Article 5 and Article 6, provided that the milestone and royalties payable to ABX with respect to such Collaboration Antigen(s) shall be governed by Section 16.8.2(a)(ii).

  • The Target Review Committee shall endeavor to reach decisions by consensus, provided that the Chair shall have final decision-making authority with respect to the attendees for each Target Review Committee meeting, the selection of Prioritized Antigens and the recommendation of Collaboration Antigens to the Research Management Committee.

  • Upon the designation of thirty-six (36) Collaboration Antigens or such other number as the Parties may mutually agree in writing, AZ shall have the right to terminate the Antigen Designation Term in its entirety on written notice to ABX.

  • The initial Proposed Antigens designated by ABX, as of the Effective Date, for selection by the Research Management Committee as Collaboration Antigens are set forth in Exhibit A-1.

  • The Parties shall establish a joint target review committee (the “Target Review Committee”), which shall oversee the review of Proposed Antigens, the selection of Prioritized Antigens and the recommendation of Collaboration Antigens for approval by the Research Management Committee.

Related to Collaboration Antigens

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Licensed Compound means [***].

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Research Program has the meaning set forth in Section 3.1.

  • Collaboration has the meaning set forth in Section 2.1.

  • Research Program Term has the meaning set forth in Section 2.2.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Research Plan shall have the meaning set forth in Section 2.1.

  • Antibody means a molecule comprising or containing one or more immunoglobulin variable domains or any fragments, derivatives, variants or modifications thereof that bind to the same antigen.

  • Collaboration Term has the meaning set forth in Section 2.1(h).

  • Collaborating physician means the physician who,

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Development Program means the implementation of the development plan.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.

  • Clinical Studies means human clinical trials for a Licensed Product and any other tests and studies for a Licensed Product in human subjects.